Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CORI

Corium International (CORI) Stock Price, News & Analysis

Corium International logo

About Corium International Stock (NASDAQ:CORI)

Key Stats

Today's Range
$12.68
$12.68
50-Day Range
N/A
52-Week Range
$7.17
$13.93
Volume
N/A
Average Volume
577,723 shs
Market Capitalization
$459.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

Receive CORI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corium International and its competitors with MarketBeat's FREE daily newsletter.

CORI Stock News Headlines

Market "Famine" Coming
Market Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...
Best International Student Loans
See More Headlines

CORI Stock Analysis - Frequently Asked Questions

Corium International, Inc. (NASDAQ:CORI) posted its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. The biopharmaceutical company earned $7.67 million during the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative net margin of 155.21% and a negative trailing twelve-month return on equity of 276.89%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corium International investors own include Bristol-Myers Squibb (BMY), Intelsat (I), Energy Transfer (ET), Iovance Biotherapeutics (IOVA), Exelixis (EXEL), SunCoke Energy Partners (SXCP) and Cypress Semiconductor (CY).

Company Calendar

Last Earnings
8/09/2018
Today
11/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CORI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-47,790,000.00
Net Margins
-155.21%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$31.86 million
Book Value
$0.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$459.65 million
Optionable
Optionable
Beta
0.87
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CORI) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners